30-day, Single-arm Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Young Children With Various Manifestations of Venous Thrombosis

Trial Profile

30-day, Single-arm Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Young Children With Various Manifestations of Venous Thrombosis

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Pulmonary embolism; Venous thromboembolism; Venous thrombosis
  • Focus Adverse reactions
  • Acronyms EINSTEINJr
  • Sponsors Bayer
  • Most Recent Events

    • 03 May 2017 Status changed from recruiting to completed.
    • 17 Mar 2017 Planned End Date changed from 1 May 2017 to 8 Apr 2017.
    • 10 Mar 2017 This trial has been completed in Austria as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top